Acute pericarditis after atrial fibrillation ablation: Incidence, characteristics, and risk factors

Shady Nakhla, MD,* Amgad Mentias, MD, Msc,† Christopher Rymer, MD,‡ Ayman Hussein, MD, FHRs,* Oussama Wazni, MD, MBA, FHRs,* John Rickard, MD, MPH,* Bryan Baranowski, MD,* Daniel Cantillon, MD, FHRs,* Allan L. Klein, MD,† Paul C. Cremer, MD,§ Tyler L. Taigen, MD*

From the *Section of Cardiac Pacing and Electrophysiology, Heart and Vascular Institute, Cleveland Clinic, Cleveland, Ohio, †Section of Clinical Cardiology, Heart and Vascular Institute, Cleveland Clinic, Cleveland, Ohio, ‡Internal Medicine, Cleveland Clinic, Cleveland, Ohio, and §Section of Cardiac Imaging Heart and Vascular Institute, Cleveland Clinic, Cleveland, Ohio.

BACKGROUND Little is known about the incidence and risk factors for the development of acute pericarditis after ablation for atrial fibrillation (AF).

OBJECTIVE The purpose of this retrospective cohort study was to describe the occurrence of and associations with suspected acute pericarditis after AF ablation.

METHODS All patients undergoing AF ablation in our center were enrolled in a prospectively maintained registry. Suspected acute pericarditis was defined as pericardial chest pain treated with disease-specific anti-inflammatory therapies within 3 months of AF ablation.

RESULTS Among 2215 patients with AF ablations between January 1, 2018, and December 31, 2019, 226 (10.2%) had suspected acute pericarditis. Treatments included colchicine in 149 patients (25%). At baseline, a lower CHADS2-VASc score and a higher body mass index were associated with pericarditis, whereas older patients were less likely to have pericarditis. With multivariable adjustment, age was associated with suspected acute pericarditis (odds ratio 0.95; 95% confidence interval 0.94–0.97; P < .0001). Among patients with suspected pericarditis, postprocedure pericardial effusion was present in 9.3% and pericarditis electrocardiographic changes in 19.5%.

CONCLUSION Suspected acute pericarditis is common after AF ablation and is associated with a younger age. Systematic assessments for acute pericarditis after AF ablation should be considered.

KEYWORDS Ablation; Acute Pericarditis; Atrial fibrillation; Inflammation; Pericarditis

Introduction
The indications for catheter ablation of atrial fibrillation (AF) have increased, and with improved mapping and ablation technology, success rates at 1 year approach 70%–80%. Complications, such as stroke, pulmonary vein stenosis, esophageal injury, and phrenic nerve paralysis, are rare and have also decreased.¹,² Acute pericarditis after AF ablation has been described, although primarily through case reports and series,³–⁵ and a broader understanding of postablation pericarditis is lacking. The putative hypothesis of postablation pericarditis relates to transmural injury of the thinner aspects of the left atrial wall resulting in an inflammatory response affecting the pericardium.⁶,⁷ Given the lack of understanding of acute pericarditis after AF ablation, the aims of the current study were 2-fold: first, to assess the incidence of suspected acute pericarditis and, second, to evaluate the associations with suspected acute pericarditis.

Methods
Study population and outcomes
Consecutive patients undergoing AF ablation at our institution from January 1, 2018, through December 31, 2019, were included and have been enrolled in a prospective outcomes registry, which includes baseline patient characteristics, procedural information, and data on AF recurrence. This outcomes and quality improvement study was approved by our institutional review board and abides by ethical standards for informed consent according to the Helsinki Declaration. The primary outcome was suspected pericarditis. Suspected acute pericarditis after AF ablation was defined as pericardial chest pain treated with disease-specific anti-inflammatories (ibuprofen at 600–800 mg every 8 hours, ...
The incidence of acute pericarditis after atrial fibrillation (AF) ablation was 10.2%.

Suspected acute pericarditis was defined as pericardial chest discomfort necessitating therapy with anti-inflammatory drugs.

At baseline, a lower CHADS2 VASc score, higher body mass index, and younger age were associated with a higher risk of developing pericarditis after AF ablation.

In a multivariable logistic regression model, younger age was associated with a higher risk of developing pericarditis after ablation, with a 1-year increase in patient age associated with a 5% decrease in the odds of developing pericarditis.

Statistical analysis
Continuous variables are given as mean ± SD and compared using the Student t test if normally distributed, and as median (interquartile range) and compared using the Mann-Whitney test if non-normally distributed. Categorical variables are given as frequencies and were compared using the χ² test or the Fisher exact test if expected cell count <5. To determine important predictors of postprocedure pericarditis, a multivariable logistic regression model was used with a stepwise selection method, with P value of .5 cutoff for model entry and cutoff value of .1 to stay in the model. The analysis was performed using SAS Version 9.4 (SAS Institute, Inc., Cary, NC).

Results
Study population and post-AF ablation pericarditis
During the study period, 2215 patients underwent AF ablation. Overall, patients were generally older, predominantly male, and 1164 (52.6%) had persistent AF (Table 1). In the entire population, 587 (26.5%) presented for a redo ablation. Cryoballoon was used in 236 patients (10.7%), and the remainder were radiofrequency ablations. Among 402 patients treated with anti-inflammatory drugs, 226 (10.2% of the entire cohort) had suspected post-AF ablation acute pericarditis. A total of 5 patients were excluded from the analysis due to pericardial complications at the time of ablation that ultimately required therapy with anti-inflammatory drugs.

Patients diagnosed with suspected post-AF ablation acute pericarditis were younger (mean age 61.4 ± 10.6 years vs 65.9 ± 9.9 years; P <.01) and more likely to have paroxysmal AF (n = 122 [54.0%] vs n = 904 [45.5%]; P = .02). Similarly, post-AF ablation pericarditis was less common in patients with hypertension (n = 122 [54.0%] vs n = 1272 [64.0%]; P = .003) and was associated with a lower CHADS2 VASc score (1.8 ± 1.4 vs 2.3 ± 1.5; P <.001). Patients with post-AF ablation pericarditis had a higher body mass index (BMI) (32 ± 8.0 kg/m² vs 30.7 ± 6.9 kg/m²; P = .02) and were more likely to present for an index ablation as opposed to redo procedure (n = 187 [82.7%] vs n = 1441 [72.4%]; P = .001). From a procedural perspective, posterior left atrial wall isolation and additional flutter lines beyond standard AF lesion sets were not associated with developing pericarditis. To identify variables associated with developing post-AF ablation acute pericarditis, a multivariable logistic regression model was used and included patient age, hypertension, diabetes, type of AF, BMI, and posterior wall ablation. Patient age was found to be the sole factor associated with developing post-AF ablation acute pericarditis (odd ratio 0.954; 95% confidence interval 0.937–0.971; P <.0001), where a 1-year increase in patient age was associated with a 5% decrease in the odds of developing pericarditis.

Most patients (n = 149 [65.9%]) received colchicine monotherapy whereas multiple drugs were given to 25% of patients (n = 57) (Table 2). Median time to diagnosis was 1 (1–1) day after AF ablation. Within the pericarditis group, 44 patients (15.9%) were found to have ECG changes consistent with pericarditis at the time of diagnosis, 21 (9.3%) had new pericardial effusions, and 9 (4.0%) had fever. Thus, 59 patients (26%) within the study definition of suspected post-AF ablation acute pericarditis would have met ESC guideline statement diagnostic criteria for acute pericarditis.

Discussion
Our study examined the incidence and risk factors of post-AF ablation acute pericarditis in a large patient population at a quaternary referral center. Our hypothesis is that thermal energy (whether radiofrequency or cryoablation), when
transmural, results in pericardial tissue injury, an ensuing inflammatory response, and pericardial chest pain. Based on our analysis, the incidence of suspected pericarditis after ablation is approximately 10%, and younger age is a risk factor. Except for higher BMI, this is also reflected in the pericarditis patient population having fewer comorbidities.

Pericardial complications due to perforation or reactive effusions in the absence of pericardial pain during catheter ablation of AF have been described. However, pericarditis after AF ablation has only been reported, and we believe under-reported, as a complication in studies evaluating catheter ablation outcomes and not as a primary objective. In the CABANA (Catheter Ablation vs Antiarrhythmic Drug Therapy for Atrial Fibrillation) trial, a 1.1% incidence (n = 11) of severe pericardial chest pain after ablation was found. Likely due to a low event rate, there is no information as to risk factors for developing pericarditis in this study or how it was managed. Furthermore, although the definition of severe pericardial chest pain in the trial is unclear, pain that is not severe is clinically meaningful as it should require treatment and does present a risk of recurrent episodes after an initial course of therapy. Mugnai et al described their series of 450 patients undergoing second-generation cryoballoon ablation for paroxysmal AF. In their analysis, 4% of patients developed acute pericarditis. Patients who went on to develop pericarditis required more cryo-applications and

Table 1  Baseline characteristics

| Variable                              | No pericarditis (N = 1989) | Pericarditis (N = 226) | P value |
|---------------------------------------|----------------------------|------------------------|---------|
| Age (y)                               | 65.9 ± 9.9                 | 61.3 ± 10.6            | <.001   |
| Female                                | 606 (30.5)                 | 72 (31.9)              | .7      |
| Paroxysmal AF                         | 904 (45.5)                 | 122 (54.0)             | .02     |
| Persistent AF                         | 1061 (53.3)                | 103 (45.6)             | .03     |
| Atrial scar                           | 662 (33.3)                 | 56 (24.8)              | .01     |
| CAD                                   | 415 (20.9)                 | 33 (14.6)              | .03     |
| CKD (creatinine >1.2)                 | 330 (16.6)                 | 38 (16.8)              | .9      |
| CHF                                   | 219 (11.0)                 | 23 (10.2)              | .7      |
| CVA                                   | 98 (4.9)                   | 6 (2.7)                | .1      |
| Diabetes                              | 319 (16.0)                 | 37 (16.4)              | .9      |
| Dialysis                              | 7 (0.4)                    | 0.0                    | .5      |
| Hypertension                          | 1272 (64.0)                | 122 (54.0)             | .003    |
| Pulmonary embolism                    | 44 (2.2)                   | 6 (2.7)                | .7      |
| Race                                  |                            |                        |         |
| White                                 | 1308 (65.8)                | 147 (65.0)             | .7      |
| Black                                 | 41 (2.1)                   | 3 (1.3)                |         |
| Other                                 | 640 (32.2)                 | 76 (33.6)              |         |
| Sleep apnea                           | 355 (17.9)                 | 47 (20.8)              | .3      |
| BMI (kg/m²)                           | 30.7 ± 6.9                 | 32 ± 8.0               | .02     |
| EF (%)                                | 55 ± 11                    | 56 ± 9.5               | .3      |
| Malignancy                            | 98 (4.9)                   | 15 (6.6)               | .3      |
| NYHA functional classification        |                            |                        |         |
| No dyspnea                            | 1084 (54.5)                | 142 (62.8)             | .09     |
| Class I                               | 486 (24.4)                 | 52 (23.0)              |         |
| Class II                              | 355 (17.9)                 | 29 (12.8)              |         |
| Class III/IV                          | 64 (3.2)                   | 3 (1.3)                |         |
| PAD                                   | 62 (3.1)                   | 4 (1.8)                | .3      |
| Creatinine (mg/dL)                    | 1.0 (0.89–1.2)             | 1.02 (0.86–1.21)       | .2      |
| Redo AF ablation                      | 548 (27.6)                 | 39 (17.3)              | .001    |
| Atrial flutter ablation               | 254 (12.8)                 | 21 (9.3)               | .1      |
| CHADS₂VASc score                      |                            |                        |         |
| Median                                | 2 (1–3)                    | 2 (1–3)                | <.001   |
| Mean                                  | 2.3 ± 1.5                  | 1.8 ± 1.4              | <.001   |
| Posterior wall ablation               | 1621 (81.5)                | 191 (84.5)             | .3      |
| Cryoballoon                           | 217 (10.9)                 | 19 (8.4)               | .3      |

Values are given as mean and standard deviation, n (%), or median (interquartile range) unless otherwise indicated.

AF = atrial fibrillation; BMI = body mass index; CAD = coronary artery disease; CHF = congestive heart failure; CKD = chronic kidney disease; EF = ejection fraction; NYHA = New York Heart Association; PAD = peripheral artery disease.

Table 2  Post-AF ablation acute pericarditis (N = 226)

| Drug choice | ECG changes | Pericardial effusion | Fever | Drug choice |
|-------------|-------------|----------------------|-------|-------------|
| Colchicine  | 44 (19.5)   | 21 (9.3)             | 9 (4.0)| Colchicine  |
| Prednisone  | 66 (29.2)   | 43 (19.0)            |       | Prednisone  |
| Ibuprofen   | 57 (25)     |                      |       | Ibuprofen   |
| Multiple drugs |        |                      |       | Multiple drugs |

Values are given as n (%).

AF = atrial fibrillation; ECG = electrocardiography.
longer freeze durations, particularly along the right inferior pulmonary vein. There were no patient specific clinical parameters that were associated with developing acute pericarditis. Darmoch et al. evaluated the incidence of acute pericarditis after AF ablation using the National Inpatient Sample and found an incidence of 0.8%. Female sex and BMI >30 were risk factors associated with developing pericarditis. Of note, the diagnosis of acute pericarditis in this sample had to be billed at discharge and likely was underreported.

Acute pericarditis after cardiac surgery has been recognized and well studied over time. In an analysis by Imazio et al., postpericardiotomy syndrome was diagnosed in 15% and was associated with female sex. Narasimhan et al. evaluated the efficacy of methotrexate in patients with refractory postprocedure pericarditis and identified 408 patients with treatment-refractory pericarditis after epicardial ablations, LARIAT suture delivery (SentreHeart, Pleasanton, CA), and open cardiac surgery; 6.1% went on to receive methotrexate for symptom resolution. Furthermore, acute pericarditis after implantable cardiac devices has been well reported to have an incidence between 1% and 5%. Some studies have implicated active fixation atrial leads in this phenomenon, resulting in microperforation along the thinner atrial walls. In both these circumstances, as well as the premise of our current analysis, trauma to the pericardium is thought to trigger the inflammatory response responsible for pericardial symptoms.

Study Limitations

Our analysis has the inherent limitations of a retrospective cohort study. A practical definition for suspected acute pericarditis was used, and fewer patients met the ESC guideline definition for acute pericarditis, although this definition has not been evaluated in patients after AF ablation. The amount of ablation delivered, mean lesion duration, and energy delivery per lesion were not obtained and may have a contributing role in developing pericardial inflammation. Finally, related to the retrospective design of our study, assessments were not systematic, and C-reactive protein measurements were not obtained routinely.

Conclusion

Acute pericarditis after AF ablation has been observed but is poorly defined. Our study demonstrated that post-AF ablation pericarditis has an incidence of 10.2%, which is higher than previously reported. Younger patients with a higher BMI but otherwise fewer comorbidities seem to be most at risk. Future studies should further delineate the mechanisms of injury and assess the efficacy of prophylactic therapies in patients at risk for post-AF ablation pericarditis.

Funding Sources: This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Disclosures: The authors have no conflicts to disclose.

Authorship: All authors attest they meet the current ICMJE criteria for authorship.

Patient Consent: The institutional review board waived the need for informed patient consent due to the use of retrospective and de-identified data.

Ethics Statement: This outcomes and quality improvement study was approved by our institutional review board and abides by ethical standards for informed consent according to the Helsinki Declaration.

References

1. Cappato R, Calkins H, Chen SA, et al. Updated worldwide survey on the methods, efficacy, and safety of catheter ablation for human atrial fibrillation. Circ Arrhythm Electrophysiol 2010;3:32–38.
2. Piccini JP, Sinner MF, Greiner MA, et al. Outcomes of Medicare beneficiaries undergoing catheter ablation for atrial fibrillation. Circulation 2012;126:2200–2207.
3. Mugnai G, de Asmundis C, Iacopino S, et al. Acute pericarditis following second-generation cryoballoon ablation for atrial fibrillation. J Interv Card Electrophysiol 2018;51:279–284.
4. Cappato R, Calkins H, Chen SA, et al. Delayed cardiac tamponade after radiofrequency catheter ablation of atrial fibrillation: a worldwide report. J Am Coll Cardiol 2011;58:2696–2697.
5. Packer DL, Mark DB, Robb RA, et al. Effect of catheter ablation vs antiarrhythmic drug therapy on mortality, stroke, bleeding, and cardiac arrest among patients with atrial fibrillation: the CABANA randomized clinical trial. JAMA 2019;321:1261–1274.
6. Imazio M, Brucato A, Rovere ME, et al. Contemporary features, risk factors, and prognosis of the post-pericardiotomy syndrome. Am J Cardiol 2011;108:1183–1187.
7. Adler Y, Charron P, Imazio M, et al. 2015 ESC guidelines for the diagnosis and management of pericardial diseases. Rev Esp Cardiol (Engl Ed) 2015;68:1126.
8. Haegele LM, Kotschet E, Byrne J, et al. Cardiac injury after percutaneous catheter ablation for atrial fibrillation. Europace 2008;10:273–275.
9. Darmoch F, AlKhala Y, et al. National trends of acute pericarditis and postprocedure pericarditis and its frequency catheter ablation of atrial fibrillation: incidence and outcomes with active-fixation atrial leads. Pacing Clin Electrophysiol 2002;25:1795.
10. Darmoch F, Al-Behary M, Al-Dahshan R, et al. Acute pericarditis after implant pericarditis: incidence and outcomes with active-fixation atrial leads. Pacing Clin Electrophysiol 2002;25:1155–1158.
11. Parsonnet V. Postpacing maximal pericarditis: incidence and outcomes with active-fixation leads. Pacemaker Clin Electrophysiol 2002;25:1795.
12. Sivakumaran S, Irwin ME, Gulambwese SS, Senaratne MF. Postpacing maximal pericarditis: incidence and outcomes with active-fixation leads. Pacemaker Clin Electrophysiol 2002;25:833–837.
13. Gatzoulis K, Archontakis S, Tsiairos D, et al. Post-cardiac injury syndrome after permanent electronic cardiac device implantation. Incidence, presentation, management and long-term prognosis. Int J Cardiol 2014;174:163–164.
14. Ellenbogen KA, Wood MA, Shepard RK. Delayed complications following pacemaker implantation. Pacemaker Clin Electrophysiol 2002;25:1155–1158.